[go: up one dir, main page]

DE60115937D1 - Piperidinverbindungen zur verwendung als antiallergika - Google Patents

Piperidinverbindungen zur verwendung als antiallergika

Info

Publication number
DE60115937D1
DE60115937D1 DE60115937T DE60115937T DE60115937D1 DE 60115937 D1 DE60115937 D1 DE 60115937D1 DE 60115937 T DE60115937 T DE 60115937T DE 60115937 T DE60115937 T DE 60115937T DE 60115937 D1 DE60115937 D1 DE 60115937D1
Authority
DE
Germany
Prior art keywords
antiallergic agents
piperidin
compounds
piperidin compounds
antiallergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60115937T
Other languages
English (en)
Other versions
DE60115937T2 (de
Inventor
G Aslanian
Neng-Yang Shih
C Ting
Y Berlin
B Rosenblum
Cormick D Mc
C Tom
W Boyce
Pietro Mangiaracina
Wa Mutahi
J Piwinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE60115937D1 publication Critical patent/DE60115937D1/de
Publication of DE60115937T2 publication Critical patent/DE60115937T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
DE60115937T 2000-10-17 2001-10-15 Piperidinverbindungen zur verwendung als antiallergika Expired - Lifetime DE60115937T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24090100P 2000-10-17 2000-10-17
US240901P 2000-10-17
PCT/US2001/032151 WO2002032893A2 (en) 2000-10-17 2001-10-15 Piperidine compounds as anti-allergic

Publications (2)

Publication Number Publication Date
DE60115937D1 true DE60115937D1 (de) 2006-01-19
DE60115937T2 DE60115937T2 (de) 2006-06-29

Family

ID=22908389

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60115937T Expired - Lifetime DE60115937T2 (de) 2000-10-17 2001-10-15 Piperidinverbindungen zur verwendung als antiallergika
DE60137461T Expired - Lifetime DE60137461D1 (de) 2000-10-17 2001-10-15 Substituierte Piperidinverbindungen zur Verwendung als H3 Histaminerezeptorantagonisten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60137461T Expired - Lifetime DE60137461D1 (de) 2000-10-17 2001-10-15 Substituierte Piperidinverbindungen zur Verwendung als H3 Histaminerezeptorantagonisten

Country Status (30)

Country Link
US (3) US6720328B2 (de)
EP (2) EP1571145B1 (de)
JP (2) JP4093859B2 (de)
KR (1) KR100567266B1 (de)
CN (2) CN1803795B (de)
AR (1) AR035497A1 (de)
AT (2) ATE420863T1 (de)
AU (2) AU1535502A (de)
BR (1) BR0114754A (de)
CA (1) CA2424664C (de)
CY (2) CY1105227T1 (de)
DE (2) DE60115937T2 (de)
DK (2) DK1326858T3 (de)
EC (1) ECSP034559A (de)
ES (2) ES2320008T3 (de)
HK (1) HK1052935B (de)
HU (1) HUP0303835A3 (de)
IL (1) IL155031A0 (de)
MX (1) MXPA03003529A (de)
NO (1) NO325997B1 (de)
NZ (1) NZ524857A (de)
PE (1) PE20020507A1 (de)
PL (1) PL361978A1 (de)
PT (1) PT1571145E (de)
RU (2) RU2301231C2 (de)
SI (1) SI1326858T1 (de)
SK (1) SK4672003A3 (de)
TW (2) TWI292399B (de)
WO (1) WO2002032893A2 (de)
ZA (1) ZA200302521B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
CN1298715C (zh) * 2001-03-13 2007-02-07 先灵公司 作为组胺h3拮抗剂的非咪唑化合物
AR036881A1 (es) * 2001-10-15 2004-10-13 Schering Corp Un proceso para la preparacion de 4-(piperidil)(2-piridil)metanona-(e)-o-metiloxima y sales
MXPA04010173A (es) * 2002-04-18 2005-02-03 Schering Corp Derivados de (1-4-piperidinil)bencimidazol utiles como antagonistas de histamina h3.
PE20040464A1 (es) 2002-04-18 2004-07-24 Schering Corp Benzimidazolonas sustituidas y derivados como antagonistas de histamina h3
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
PT1539742E (pt) * 2002-06-24 2007-01-31 Schering Corp Derivados de índole úteis como antagonistas h3 de histamina
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
MY138201A (en) 2002-09-04 2009-05-29 Schering Corp Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
WO2004066960A2 (en) * 2003-01-28 2004-08-12 Schering Corporation Combination of h1, h3 and h4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
CA2523431A1 (en) * 2003-04-23 2004-11-25 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US20060247227A1 (en) * 2003-07-18 2006-11-02 Bailey James M Substituted piperidines as histamine h3 receptor ligands
EP1819329A2 (de) * 2004-08-04 2007-08-22 Schering Corporation Pharmazeutische formulierungen mit pleconaril zur behandlung von atemwegserkrankungen
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
US7408066B2 (en) * 2005-06-20 2008-08-05 Schering Corproation Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
EP1902046B1 (de) 2005-06-20 2009-12-02 Schering Corporation Als antagonisten von histamin h3 geeignete piperidinderivate
EP1931665A1 (de) * 2005-09-20 2008-06-18 Schering Corporation Als histamin-h3-antagonist geeignetes 1-[[1-[(2-amin0-6-methyl-4-pyridinyl)methyl]-4-fluor-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3h-imidazo[4,5-b]pyridin-3-yl]piperidin
EP1962835A2 (de) * 2005-12-21 2008-09-03 Schering Corporation Behandlung nicht alkoholinduzierter fettleber mittels cholesterinsenkenden mitteln und/oder h3-rezeptor-antagonisten oder -inversagonisten
MX2008008339A (es) 2005-12-21 2008-09-03 Schering Corp Derivados de anilina sustituida ùtiles como antagonistas de la histamina h3.
KR20080081321A (ko) * 2005-12-21 2008-09-09 쉐링 코포레이션 Ｈ3 길항제/역 작용제 및 식욕 억제제의 조합물
KR20080087833A (ko) * 2005-12-21 2008-10-01 쉐링 코포레이션 히스타민 ｈ３ 길항제로서 유용한 페녹시피페리딘 및 이의유사체
NZ569814A (en) 2006-01-18 2011-10-28 Schering Corp Cannibinoid receptor modulators
CL2008000594A1 (es) * 2007-03-02 2008-09-05 Schering Corp Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
EP2548874A3 (de) * 2007-06-28 2013-05-15 Intervet International B.V. Substituierte Piperazine als CB1-Antagonisten
HRP20110953T1 (hr) * 2007-10-17 2012-01-31 Sanofi Supstituirani n-fenilbipirolidinkarboksamidi i njihova upotreba u terapiji
PT2212283E (pt) * 2007-10-17 2011-11-03 Sanofi Sa Carboxamidas de n-fenil-bipirrolidina substituídas e sua utilização terapêutica
NZ584691A (en) * 2007-10-17 2011-09-30 Sanofi Aventis Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
PL2215058T3 (pl) * 2007-10-17 2012-04-30 Sanofi Sa Podstawione N-fenylo-bipirolidynomoczniki oraz ich zastosowanie terapeutyczne
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
PL2240018T3 (pl) * 2008-01-04 2017-01-31 Schabar Res Ass Llc Kompozycja zawierająca środek przeciwbólowy i przeciwhistaminowy
WO2010027567A2 (en) 2008-07-23 2010-03-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
EP2350048A2 (de) 2008-10-16 2011-08-03 Schering Corporation Azinderivate und verfahren zu deren anwendung
EP2379565A1 (de) 2008-12-19 2011-10-26 Schering Corporation Piperidin- und piperazinderivate und verfahren zu deren verwendung
US8283360B2 (en) 2008-12-19 2012-10-09 Merck Sharp & Dohme Corp. Bicyclic heterocyclic derivatives and methods of use thereof
CA2759714A1 (en) * 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
TW201111392A (en) 2009-06-16 2011-04-01 Schering Corp Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
US8785440B2 (en) 2009-09-04 2014-07-22 Biogen Idec Ma, Inc. Bruton's tyrosine kinase inhibitors
EP2527340B1 (de) * 2010-01-22 2016-08-17 Taiho Pharmaceutical Co., Ltd. Piperazinverbindung mit pgds-inhibierender wirkung
EP2619198A1 (de) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulatoren des gpr119-rezeptors und behandlung von damit assoziierten erkrankungen
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
CN105315267B (zh) * 2014-07-30 2019-06-04 江苏恩华药业股份有限公司 一种酰胺类衍生物及其应用
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
CN110049976A (zh) 2016-07-21 2019-07-23 比奥根Ma公司 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
CN110105263A (zh) * 2019-05-13 2019-08-09 常州大学 一种阿米卡星中间体的合成方法
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
CA3124579A1 (en) 2020-07-15 2022-01-15 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
WO2022015784A1 (en) 2020-07-15 2022-01-20 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6062590A (en) 1989-07-07 1991-02-06 Schering Corporation Pharmaceutically active compounds
ZA929788B (en) 1991-12-18 1993-06-22 Schering Corp Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring.
US5807872A (en) 1992-12-16 1998-09-15 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
US5633250A (en) 1991-12-18 1997-05-27 Schering Corporation Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
ES2188649T3 (es) 1993-11-15 2003-07-01 Schering Corp Fenil-alquil-imidazoles como antagonistas del receptor h3.
EP0920425B1 (de) * 1995-11-17 2003-02-19 Aventis Pharmaceuticals Inc. Substituierte 4-(1h-benzimidazol-2-yl-amino)piperidine zur behandlung allergischer erkrankungen
MY116130A (en) 1996-08-16 2003-11-28 Schering Corp Treatment of upper airway allergic responses
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
US5990147A (en) 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
JP2001522835A (ja) * 1997-11-07 2001-11-20 シェーリング コーポレイション フェニル−アルキル−イミダゾール型のｈ３レセプターリガンド
US6034251A (en) 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
RU2135454C1 (ru) * 1998-03-30 1999-08-27 Сосна Михаил Хаймович Переработка природного газа с получением метанола
JP2002527381A (ja) * 1998-10-09 2002-08-27 シェーリング コーポレイション アレルギー性疾患を処置するための組成物および方法
US6100279A (en) 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
CN1298715C (zh) 2001-03-13 2007-02-07 先灵公司 作为组胺h3拮抗剂的非咪唑化合物
US7105505B2 (en) * 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
PE20040464A1 (es) * 2002-04-18 2004-07-24 Schering Corp Benzimidazolonas sustituidas y derivados como antagonistas de histamina h3
PT1539742E (pt) * 2002-06-24 2007-01-31 Schering Corp Derivados de índole úteis como antagonistas h3 de histamina
US20040198743A1 (en) * 2003-01-31 2004-10-07 Schering Corporation Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists

Also Published As

Publication number Publication date
ES2250500T3 (es) 2006-04-16
BR0114754A (pt) 2003-07-01
RU2007104096A (ru) 2008-08-10
RU2301231C2 (ru) 2007-06-20
JP4093859B2 (ja) 2008-06-04
US7300941B2 (en) 2007-11-27
AR035497A1 (es) 2004-06-02
EP1326858B1 (de) 2005-12-14
ATE420863T1 (de) 2009-01-15
CN1803795B (zh) 2010-05-12
ES2320008T3 (es) 2009-05-18
NO20031744D0 (no) 2003-04-15
CN1243751C (zh) 2006-03-01
HK1081182A1 (en) 2006-05-12
PT1571145E (pt) 2009-04-07
JP2007145866A (ja) 2007-06-14
CA2424664A1 (en) 2002-04-25
AU2002215355B2 (en) 2006-09-14
DE60115937T2 (de) 2006-06-29
DE60137461D1 (de) 2009-03-05
EP1571145A1 (de) 2005-09-07
US6720328B2 (en) 2004-04-13
HK1052935A1 (en) 2003-10-03
IL155031A0 (en) 2003-10-31
KR20030036931A (ko) 2003-05-09
CY1110262T1 (el) 2015-01-14
EP1326858A2 (de) 2003-07-16
PL361978A1 (en) 2004-10-18
AU1535502A (en) 2002-04-29
US20080119487A1 (en) 2008-05-22
NO325997B1 (no) 2008-09-01
CY1105227T1 (el) 2010-03-03
DK1571145T3 (da) 2009-05-04
ATE312833T1 (de) 2005-12-15
DK1326858T3 (da) 2006-05-08
KR100567266B1 (ko) 2006-04-03
SK4672003A3 (en) 2003-11-04
PE20020507A1 (es) 2002-06-25
HUP0303835A3 (en) 2009-08-28
TWI258474B (en) 2006-07-21
HK1052935B (en) 2006-05-19
JP2004511553A (ja) 2004-04-15
US20040097513A1 (en) 2004-05-20
TW200510368A (en) 2005-03-16
CN1469873A (zh) 2004-01-21
NZ524857A (en) 2004-12-24
CA2424664C (en) 2008-12-23
EP1571145B1 (de) 2009-01-14
ECSP034559A (es) 2003-06-25
SI1326858T1 (sl) 2006-04-30
MXPA03003529A (es) 2003-08-07
CN1803795A (zh) 2006-07-19
NO20031744L (no) 2003-06-14
ZA200302521B (en) 2004-06-30
WO2002032893A3 (en) 2002-08-22
HUP0303835A2 (hu) 2004-03-01
TWI292399B (en) 2008-01-11
US20030045519A1 (en) 2003-03-06
WO2002032893A2 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
DE60115937D1 (de) Piperidinverbindungen zur verwendung als antiallergika
ATE277933T1 (de) Thiophenverbindungen zur verwendung als antikrebsmittel
ATE485272T1 (de) Polyarylcarboxamide zur verwendung als lipidsenker
DE60140366D1 (de) Piperidinverbindungen zur verwendung als ccr-3-inhibitoren
IL152209A0 (en) Benzoamide piperidine compounds as substance p antagonists
DE60021371D1 (de) Piperidinderivate verwendbar als ccr5 antagonisten
DK1448523T3 (da) Heterocycliske forbindelser samt metoder til anvendelse deraf
DE60018792D1 (de) Heterocyclo-alkylsulfonylpyrazolderivate zur verwendung als anti-imflammatorische oder analgetische verbindungen
AR027983A1 (es) Novedosos compuestos
NO20032390L (no) Serotonerge midler
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
DE50107230D1 (de) Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer
DE60230491D1 (de) Als ccr5-antagonisten verwendbare aryloxim-piperazine
PT1299356E (pt) Novos compostos
ATE277053T1 (de) 2-(4-pyridinyl)-benzofurane zur verwendung als metalloprotease-inhibitoren
AR028220A1 (es) Novedosos compuestos
DE60210254D1 (de) Aminosubstituierter hypocrelline zur verwendung als sonosensitizer
ATE280161T1 (de) Imidazolverbindungen als alpha2-adrenorezeptoren antagonisten
DE60127917D1 (de) Verwendung von gamma-CEHC als Antioxidantien
AR028399A1 (es) Nuevos compuestos
ATE321571T1 (de) Aminosubstituierter hypocrelline zur verwendung als sonosensitizer
SE0001804D0 (sv) New compounds II
SE0003437D0 (sv) Novel compounds
SE0003436D0 (sv) Novel compounds
SE0002331D0 (sv) Novel compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition